Lv3
354 积分 2025-03-12 加入
Bavdegalutamide (ARV-110): a potent PROTAC androgen receptor degrader for the treatment of metastatic-castration resistant prostate cancer
3个月前
已关闭
Clinical Application of PARP1 Inhibitors and Challenges in Cancer Therapy
4个月前
已完结
SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance
5个月前
已完结
Dietary sialic acids: distribution, structure, and functions
5个月前
已完结
A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models
6个月前
已完结
Global patterns and trends in breast cancer incidence and mortality across 185 countries
7个月前
已完结
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs
7个月前
已完结
How protein-slayer drugs could beat some of the cruellest cancers
7个月前
已完结
Lessons learned in linking PROTACs from discovery to the clinic
7个月前
已完结
E3 ligase ligand chemistries: from building blocks to protein degraders
7个月前
已完结
皖公网安备34019202002308
